JP2025507571A5 - - Google Patents
Info
- Publication number
- JP2025507571A5 JP2025507571A5 JP2024548426A JP2024548426A JP2025507571A5 JP 2025507571 A5 JP2025507571 A5 JP 2025507571A5 JP 2024548426 A JP2024548426 A JP 2024548426A JP 2024548426 A JP2024548426 A JP 2024548426A JP 2025507571 A5 JP2025507571 A5 JP 2025507571A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutical composition
- lnp
- cancer
- antigenic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311716P | 2022-02-18 | 2022-02-18 | |
| US63/311,716 | 2022-02-18 | ||
| US202263381460P | 2022-10-28 | 2022-10-28 | |
| US63/381,460 | 2022-10-28 | ||
| PCT/US2023/062844 WO2023159197A1 (en) | 2022-02-18 | 2023-02-17 | Mrnas encoding checkpoint cancer vaccines and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507571A JP2025507571A (ja) | 2025-03-21 |
| JP2025507571A5 true JP2025507571A5 (https=) | 2026-02-26 |
Family
ID=85703979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548426A Pending JP2025507571A (ja) | 2022-02-18 | 2023-02-17 | チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250213664A1 (https=) |
| EP (1) | EP4479085A1 (https=) |
| JP (1) | JP2025507571A (https=) |
| TW (1) | TW202345864A (https=) |
| WO (1) | WO2023159197A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026008017A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
| WO2026008026A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Pd-l1 cancer vaccines and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| EP2288336B8 (en) | 2008-04-25 | 2017-03-22 | Northwestern University | Nanostructures suitable for sequestering cholesterol |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| JP6948313B6 (ja) * | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| HRP20240052T1 (hr) * | 2016-03-04 | 2024-03-29 | Io Biotech Aps | Kombinirana terapija protiv raka |
| JP7194594B2 (ja) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| CN110402145A (zh) * | 2016-10-26 | 2019-11-01 | 莫得纳特斯公司 | 用于增强免疫应答的信使核糖核酸及其使用方法 |
-
2023
- 2023-02-17 US US18/839,326 patent/US20250213664A1/en active Pending
- 2023-02-17 WO PCT/US2023/062844 patent/WO2023159197A1/en not_active Ceased
- 2023-02-17 EP EP23711903.7A patent/EP4479085A1/en active Pending
- 2023-02-17 TW TW112105879A patent/TW202345864A/zh unknown
- 2023-02-17 JP JP2024548426A patent/JP2025507571A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7304629B2 (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| JP2025507571A5 (https=) | ||
| BR112017005821B1 (pt) | Kit compreendendo lipossoma de dope/dotma/dotap e rna, método para a preparação de uma composição farmacêutica e método para quimicamente estabilizar uma dispersão lipossômica aquosa | |
| TW201408309A (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| EA037217B1 (ru) | Композиция и вакцина для лечения рака легких | |
| Katakami et al. | Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer | |
| WO2008086610A1 (en) | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity | |
| JP2022547298A5 (https=) | ||
| JP2024520477A (ja) | ペプチドに基づくネオ抗原ワクチンの多成分化学組成物 | |
| AU2020317239A1 (en) | Anti-neoplastic combined pharmaceutical composition and application thereof | |
| WO2015027915A1 (zh) | 体内个体化系统免疫治疗方法和装置 | |
| JP2022539157A5 (https=) | ||
| WO2018101831A1 (en) | Pharmaceutical composition for use in the treatment of cancer | |
| JP2022512384A5 (https=) | ||
| JP2021536239A5 (https=) | ||
| Zhang et al. | A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research | |
| US20250319172A1 (en) | Anticancer vaccine composition comprising hsp90 antigenic peptide and use thereof | |
| EP2966092A1 (en) | Novel peptide having 5 linked ctl epitopes | |
| JP2019532635A (ja) | 腫瘍溶解性ウイルスを腫瘍に標的化する方法 | |
| CN115920019A (zh) | 一种治疗肺癌及其骨转移的mRNA疫苗及其制备方法与应用 | |
| US20140363464A1 (en) | Pre- or post-exposure treatment for filovirus or arenavirus infection | |
| EP4378473A1 (en) | Her2 vaccine composition | |
| JP2016520073A (ja) | Ｍｕｃ−１リポペプチドによるワクチン免疫で肺癌を治療する方法 | |
| CN113440533A (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JP7062754B2 (ja) | ｈａＮＫセツキシマブ併用及び方法 |